Author + information
- Kent Y. Feng, MDa,
- Rahul S. Loungani, MDb,
- Vishal N. Rao, MD, MPHb,
- Chetan B. Patel, MDb,c,
- Michel G. Khouri, MDb,c,
- G. Michael Felker, MD, MHSb,c and
- Adam D. DeVore, MD, MHSb,c,∗ (, )@_adevore@DukeHFDoc
- aStanford Center for Clinical Research, Stanford University School of Medicine, Stanford, California
- bDivision of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina
- cDuke Clinical Research Institute, Durham, North Carolina
- ↵∗Address for correspondence:
Dr. Adam D. DeVore, Duke Clinical Research Institute, 200 Morris Street, #6318, Durham, North Carolina 27701.
• Prognostic factors for ATTR-CM can guide patient expectations and inform clinical decisions.
• Clinical features, blood biomarkers, and imaging obtained during workup for ATTR-CM convey prognostic information.
• Further studies in determining the incremental value of prognostic factors are warranted.
Transthyretin amyloid cardiomyopathy (ATTR-CM) has emerged as an increasingly identified etiology of heart failure. Fortunately, the disease now has an approved therapy, with many others under development. Assessment of prognosis in ATTR-CM is critical to inform patients about the disease course and guide clinical decisions. This review discusses the evidence behind clinical, biomarker, and imaging findings that inform prognosis in patients with ATTR-CM and can assist providers in the shared decision-making process during management of this disease.
This paper was funded by the Duke Clinical Research Institute. Dr. Khouri has received research support from and is a member of the Speakers Bureau of Alnylam Pharmaceuticals; and has received an honorarium from and a member of the Advisory Board of Pfizer. Dr. Felker has received research support from Amgen, Merck, Novartis, Otsuka America Pharmaceutical, and Roche Diagnostics; and has served as a consultant for Amgen, Bristol-Myers Squibb, GlaxoSmithKline, Medscape, LLC, Medtronic PLC, MyoKardia, Novartis, Trevena, Alynylam Pharmaceuticals, and Cardionomic. Dr. DeVore has received support from the American Heart Association, Amgen, the National Heart, Lung, and Blood Institute, and Novartis; and has been a consultant for Novartis. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received September 16, 2019.
- Revision received October 30, 2019.
- Accepted November 4, 2019.
- 2019 The Authors